Research ArticleDrug Discovery and Translational Medicine
Pharmacological Characterization of a Novel Beta3 Adrenergic Agonist, Vibegron: Evaluation of Anti-Muscarinic Receptor Selectivity for Optimal Combination Therapy for Overactive Bladder.
Jerry Di Salvo, Hiroshi Nagabukuro, Alexandra Wickham, Catherine Abbadie, Julie A. DeMartino, Aileen Fitzmaurice, Loise Gichuru, Alison Kulick, Marcie J Donnelly, Nina Jochnowitz, Amanda Hurley, Antonio Pereira, Anthony Sanfiz, Gregory Veronin, Katherine Villa, John Woods, Beata Zamlynny, Emanuel Zycband, Gino M Salituro, Tara Frenkl, Ann E Weber, Scott D Edmondson and Mary Struthers
Journal of Pharmacology and Experimental Therapeutics December 13, 2016, jpet.116.237313; DOI: https://doi.org/10.1124/jpet.116.237313
Jerry Di Salvo
1 Merck & Co Inc;
Hiroshi Nagabukuro
2 Takeda Pharmaceutical Co;
Alexandra Wickham
3 Merck;
Catherine Abbadie
4 Sunovion Pharmaceuticals;
Julie A. DeMartino
5 EMD Serono;
Aileen Fitzmaurice
6 Regeneron;
Loise Gichuru
3 Merck;
Alison Kulick
3 Merck;
Marcie J Donnelly
7 BMS;
Nina Jochnowitz
3 Merck;
Amanda Hurley
8 Mount Sinai;
Antonio Pereira
3 Merck;
Anthony Sanfiz
9 NYU;
Gregory Veronin
10 Rutgers;
Katherine Villa
11 MIT;
John Woods
12 Retired
Beata Zamlynny
3 Merck;
Emanuel Zycband
3 Merck;
Gino M Salituro
3 Merck;
Tara Frenkl
3 Merck;
Ann E Weber
12 Retired
Scott D Edmondson
3 Merck;
Data Supplement
Files in this Data Supplement:
- Supplemental Data - 4 supplemental figures.